Table 2. Summary of type 17 T-cell types by human cancers and its associated prognosis.
| Cancer Type | Endogenous, tumor-infiltrating type 17 T-cells found | Overall survival | Ref. |
|---|---|---|---|
| Acute leukemia | Th17 | Improved | (32) |
| Acute myeloid leukemia | Tc17 | Poor | (33) |
| Breast | Th17 | Poor* | (34,35) |
| Colorectal cancer | gdT17, Th17 | Poor | (28,36,37,38) |
| Cervical carcinoma | Th17 | Improved† | (39) |
| Cervical squamous cell carcinoma | CD3+ IL17+ | Improved‡ | (40) |
| Esophageal squamous cell carcinoma | IL17+ cells | Improved | (41,42) |
| Gastric carcinoma | Th17 | Poor | (43,44) |
| Hepatocellular carcinoma | Tc17, Th17 | Poor | (45,46,47) |
| Lung cancer | Th17 | Improved | (48) |
| Lung carcinoma | Th17, gdT17 | Improved | (49,50) |
| Melanoma | Th17, Tc17 | Poor | (51) |
| Myeloma | Th17 | Poor | (52,53) |
| Nasopharyngeal | Th17, Tc17 | Improved? | (54) |
| Nasopharyngeal carcinoma | IL17+ cells | No correlation | (54,55) |
| Non-small cell lung | Th17 | Poor | (56,57) |
| Ovarian | Th17 | Improved | (58,59) |
| Pancreatic | Th17 | Poor | (60) |
| Prostate | Th17, NKT17 | Improved§ | (61,62) |
| Renal cell carcinoma | Th17 | Improved | (63) |
| Small cell lung | Th17 (peripheral) | Improved | (64) |
*Improved survival was observed in non-inflamed triple negative breast cancer. †In cervical carcinoma, IL-17 level as a whole was associated with poor outcome, due to the pro-tumorigenic contributions of IL-17 producing neutrophils. ‡Prognosis for IL-17+ cells in general was poor for cervical squamous cell carcinoma. §The prognosis for IL-17 producing cells in hormone-resistant prostate cancer.